Cargando…

Survival with low- and high-flux dialysis

BACKGROUND: Besides advances in haemodialysis (HD), mortality rates are still high. The effect of the different types of HD membranes on survival is still a controversial issue. The aim of this COSMOS (Current management Of Secondary hyperparathyroidism: a Multicentre Observational Study) analysis w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez-Álvarez, Emilio, Rodríguez-García, Minerva, Locatelli, Francesco, Zoccali, Carmine, Martín-Malo, Alejandro, Floege, Jürgen, Ketteler, Markus, London, Gerard, Górriz, José L, Rutkowski, Boleslaw, Ferreira, Anibal, Pavlovic, Drasko, Cannata-Andía, Jorge B, Fernández-Martín, José L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323142/ https://www.ncbi.nlm.nih.gov/pubmed/34345415 http://dx.doi.org/10.1093/ckj/sfaa233

Ejemplares similares

Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis
por: Martín-Carro, Beatriz, et al.
Publicado: (2023)

The European Certificate in Nephrology: towards harmonization and excellence in training
por: Cannata-Andía, Jorge B, et al.
Publicado: (2018)

Ultrasonographic Evaluation of Parathyroid Hyperplasia in Dialysis Patients
por: Pavlovic, Drasko, et al.
Publicado: (2006)

Cardiovascular and renal medicine, an expanding territory
por: Zoccali, Carmine, et al.
Publicado: (2011)

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide
por: Covic, Adrian C., et al.
Publicado: (2017)

THE ASSOCIATION OF LOW TRIIODOTHYRONINE SYNDROME, PROTEIN-ENERGY WASTING AND CHRONIC INFLAMMATION WITH MORTALITY IN PREVALENT DIALYSIS PATIENTS
por: Črne Fureš, Nataša, et al.
Publicado: (2018)

11. Laboratory Standards in the Diagnosis and Monitoring of Therapy
por: Pavlović, Draško
Publicado: (2009)

Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?
por: Jager, Kitty J, et al.
Publicado: (2011)

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease–mineral bone disorder parameters in dialysis patients
por: Ketteler, Markus, et al.
Publicado: (2019)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

The future of European Nephrology ‘Guidelines’—a declaration of intent by European Renal Best Practice (ERBP)
por: Vanholder, Raymond, et al.
Publicado: (2009)

Dialyzer Reuse and Outcomes of High Flux Dialysis
por: Argyropoulos, Christos, et al.
Publicado: (2015)

Cost-effectiveness analysis of online hemodiafiltration versus high-flux hemodialysis
por: Ramponi, Francesco, et al.
Publicado: (2016)

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2014)

Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
por: Jankowska, Magdalena, et al.
Publicado: (2015)

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
por: Floege, Jürgen, et al.
Publicado: (2015)

Management of hyperphosphataemia in chronic kidney disease—challenges and solutions
por: Ketteler, Markus, et al.
Publicado: (2013)

Vascular calcifications, vertebral fractures and mortality in haemodialysis patients
por: Rodríguez-García, Minerva, et al.
Publicado: (2009)

Are there sex differences in cardiovascular outcomes in non-dialysis CKD patients?
por: Provenzano, Pasquale Fabio, et al.
Publicado: (2023)

Editorial: Management of Patients With Non-dialysis Dependent Chronic Kidney Disease (ND-CKD)
por: Provenzano, Michele, et al.
Publicado: (2022)

The relationship between the physician and pharmaceutical industry: background ethics and regulation proposals
por: Keller, Frieder, et al.
Publicado: (2016)

Effects of Low-Flux and High-Flux Dialysis Membranes on Erythropoietin Responsiveness in Hemodialysis Patients
por: Abdelhamid, Walid A. R., et al.
Publicado: (2022)

Influence of megestrol acetate on nutrition, inflammation and quality of life in dialysis patients
por: Gołębiewska, Justyna E., et al.
Publicado: (2011)

Homoarginine and Mortality in Pre-Dialysis Chronic Kidney Disease (CKD) Patients
por: Ravani, Pietro, et al.
Publicado: (2013)

Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences
por: Panizo, Sara, et al.
Publicado: (2021)

Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s
por: Ketteler, Markus, et al.
Publicado: (2022)

Neck swelling secondary to severe hyperplasia of autotransplanted parathyroid tissue following parathyroidectomy
por: Pavlovic, Drasko, et al.
Publicado: (2008)

Vitamin D in the Patients with Chronic Kidney Disease: When, to Whom and in Which Form
por: Pavlovic, Drasko, et al.
Publicado: (2015)

The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS
por: Cannata-Andía, Jorge B., et al.
Publicado: (2008)

Promoting scientific collaboration and education in cardiovascular–renal medicine: EURECAM: An ERA-EDTA-based working group
por: Covic, Adrian, et al.
Publicado: (2009)

Dialysis: History, Development and Promise
por: Locatelli, Francesco
Publicado: (2013)

Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
por: Cunningham, John, et al.
Publicado: (2008)

Half a century of haemodialysis: two patient journeys
por: Pavlovic, Drasko, et al.
Publicado: (2022)

Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study
por: Kanda, Eiichiro, et al.
Publicado: (2020)

Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease
por: Ketteler, Markus, et al.
Publicado: (2021)

The Effect of Dialysis Membrane Flux on Amino Acid Loss in Hemodialysis Patients
por: Gil, Hyo-Wook, et al.
Publicado: (2007)

Cystatin C: An alternative dialysis adequacy marker in high flux hemodialysis
por: Maheshwari, K. U., et al.
Publicado: (2015)

Oxidative Stress as Estimated by Gamma-Glutamyl Transferase Levels Amplifies the Alkaline Phosphatase-Dependent Risk for Mortality in ESKD Patients on Dialysis
por: Torino, Claudia, et al.
Publicado: (2016)

Updated programme for harmonization of training in nephrology in the European Union
por: Lappin, David W.P., et al.
Publicado: (2013)

When comparing the safety of drugs, don't forget the exposure dimension
por: Zoccali, Carmine
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1uq3ag6hk338hmfpcm37pt83o2